Code | Full name of the interventions that prioritized in Fig. 4 |
---|---|
4.9 | Drug therapy (including glycaemic control for diabetes mellitus and control of hypertension using a total risk* approach) and counseling to individuals who have had a heart attack or stroke and to persons with high risk (≥ 30%) of a fatal and non-fatal cardiovascular event in the next 10 years |
4.10 | Treatment of new cases of acute myocardial infarction** with either: acetylsalicylic acid, or acetylsalicylic acid and clopidogrel, or thrombolysis, or primary percutaneous coronary interventions (PCI) |
4.11 | Treatment of acute ischemic stroke with intravenous thrombolytic therapy |
4.15 | Cardiac rehabilitation post-myocardial infarction |
4.16 | Anticoagulation for medium-and high-risk non-valvular atrial fibrillation and for mitral stenosis with atrial fibrillation |
4.14 | Treatment of congestive cardiac failure with angiotensin-converting-enzyme inhibitor, beta-blocker, and diuretic |
4.13 | Secondary prevention of rheumatic fever and rheumatic heart disease by developing a register of patients who receive regular prophylactic penicillin |
4.12 | Primary prevention of rheumatic fever and rheumatic heart diseases by increasing appropriate treatment of streptococcal pharyngitis at the primary care level |
4.17 | Low-dose acetylsalicylic acid for ischemic stroke |
4.18 | Care of acute stroke and rehabilitation in stroke units |
4.27 | Prevention of cervical cancer by screening women aged 30–49 years |
4.26 | Vaccination against human papillomavirus (2 doses) of 9–13-year-old girls |
4.28 | Screening with mammography (once every 2 years for women aged 50–69 years) linked with timely diagnosis and treatment of breast cancer |
4.29 | Treatment of colorectal cancer stages I and II with surgery +/− chemotherapy and radiotherapy |
4.34 | Symptom relief for patients with chronic obstructive pulmonary disease with inhaled salbutamol |
4.19 | Preventive foot care for people with diabetes (including educational programs, access to appropriate footwear, multidisciplinary clinics |
4.21 | Effective glycaemic control for people with diabetes, along with standard home glucose monitoring for people treated with insulin to reduce diabetes complications |
4.20 | Diabetic retinopathy screening for all diabetes patients and laser photocoagulation for prevention of blindness |
4.33 | Symptom relief for patients with asthma with inhaled salbutamol |
4.35 | Treatment of asthma using low dose inhaled beclometasone and short-acting beta-agonist |
4.32 | Population-based colorectal cancer screening, including through a faecal occult blood test, as appropriate, at age > 50 years, linked with timely treatment |
4.31 | Oral cancer screening in high-risk groups (for example, tobacco users, betel-nutchewers) linked with timely treatment |
4.30 | Prevention of liver cancer through hepatitis B immunization |
4.25 | Screening of people with diabetes for proteinuria and treatment with angiotensin-converting enzyme inhibitor for the prevention and delay of renal disease |
4.37 | Cost-effective interventions to prevent occupational lung diseases, for example, from exposure to silica, asbestos |
4.38 | Influenza vaccination for patients with chronic obstructive pulmonary disease |
4.23 | Influenza vaccination for patients with diabetes |
4.22 | Lifestyle interventions for preventing type 2 diabetes |
4.24 | Preconception care among women of reproductive age who have diabetes including patient education and intensive glucose management |
4.36 | Access to improved stoves and cleaner fuels to reduce indoor air pollution |